Search

Author/Creator Almond, Lisa M.

2. Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19. Issue 6 (6th April 2022)

Authors:
Hong, Eunjin; Almond, Lisa M.; Chung, Peter S.; Rao, Adupa P.; Beringer, Paul M.
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 111:Issue 6(2022)
Page Start:
1324
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series. Issue 4 (12th March 2023)

Authors:
Hong, Eunjin; Li, Regina; Shi, Alan; Almond, Lisa M.; Wang, Joshua; Khudari, Amin Z.; Haddad, Soumar; Sislyan, Sarkis; Angelich, Marissa; Chung, Peter S.; Rao, Adupa P.; Beringer, Paul M.
Journal:
Pharmacotherapy
Issue:
Volume 43:Issue 4(2023)
Page Start:
291
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗